Stock of Danish vaccine producer drops

After a surge of nearly 50 percent last week, the share price of Bavarian Nordic, the sole maker of an approved monkeypox vaccine, fell by about four percent on Monday. The WHO’s declaration of the monkeypox outbreak in Africa as a global health crisis had spiked Bavarian Nordic’s shares. The company sold 15 million vaccine doses during the last epidemic and expects to deliver two million doses by the end of this year, with capacity for an extra 10 million doses by 2025. Denmark has seen only a few cases this year, in contrast to Sweden which reported its first case linked to the current outbreak last week. Africa has experienced 16,000 cases with 500 deaths in the Democratic Republic of Congo and its neighbors. Bavarian Nordic is set to release its half-year financial results shortly.